Metacrine to Present Phase 1 Results of MET409, an Optimized Next Generation FXR Agonist at The International Liver Congress (EASL) 2019

SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) — Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, will present data showing MET409, a potent, systemic and sustained non-bile acid….


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.